ELURYNG

Post-LOE

etonogestrel and ethinyl estradiol

Teva

ANDAVAGINALRING

Approved

Dec 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ELURYNG (etonogestrel and ethinyl estradiol) by Teva is estrogen receptor agonists [moa]. Approved for pregnancy. First approved in 2019.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Estrogen Receptor Agonists

Pharmacologic Class:

Estrogen

Indications (1)

pregnancy

Company

Worked on ELURYNG at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.